Clinicopathological correlates of activating gnas mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas

Annals of Surgical Oncology

Volumn 20, Issue 12, 2013, Pages 3802-3808

  Dal Molin, Marco ^a,b   Matthaei, Hanno ^a,c   Wu, Jian ^a   Blackford, Amanda ^a   Debeljak, Marija ^a   Rezaee, Neda ^a   Wolfgang, Christopher L ^a   Butturini, Giovanni ^b   Salvia, Roberto ^b   Bassi, Claudio ^b   Goggins, Michael G ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a   Eshleman, James R ^a   Hruban, Ralph H ^a   Maitra, Anirban ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CODON; COHORT ANALYSIS; DISEASE ASSOCIATION; DNA EXTRACTION; FEMALE; GENE MUTATION; GNAS GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; ONCOGENE; OVERALL SURVIVAL; PREVALENCE; PYROSEQUENCING; TUMOR LOCALIZATION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84886086035     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3096-1     Document Type: Article

References (26)

1. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977-87.
2. Longnecker DS, Adsay NV, Fernandez-del Castillo C, et al. Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas. 2005;31:344-9.
3. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839-48.
4. Adsay NV. Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg. 2008;12:401-4.
5. Maitra A, Fukushima N, Takaori K, Hruban RH. Precursors to invasive pancreatic cancer, Adv Anat Pathol. 2005;12:81-91.
6. Correa-Gallego C, Ferrone CR, Thayer SP, et al. Incidental pancreatic cysts: do we really know what we are watching? Pancreatology. 2010;10:144-50.
7. Salvia R, Malleo G, Marchegiani G, et al. Pancreatic resections for cystic neoplasms: from the surgeon's presumption to the pathologist's reality. Surgery. 2012;152:S135-42.
8. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92ra66.
9. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA. 2011;108:21188-93.
10. Matthaei H, Norris AL, Tsiatis AC, et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2012;255:326-33.
11. Hruban RH, Klimstra DS, Pitman MB. Tumors of the pancreas. Washington, DC: American Registry of Pathology; 2006.
12. Furukawa T, Kloppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794-9.
13. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
14. Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. GNAS: normal and abnormal functions (minireview). Endocrinology. 2004;145:5459-64.
15. Kanda M, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut. 2013;62(7):1024-33.
16. Chen G, Olson MT, O'Neill A, et al. A virtual pyrogram generator to resolve complex pyrosequencing results. J Mol Diagn. 2012;14:149-59.
17. Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep. 2011;1:161.
18. Kalfa N, Lumbroso S, Boulle N, et al. Activating mutations of Gsα in kidney cancer. J Urol. 2006;176:891-5.
19. Collins MT, Sarlis NJ, Merino MJ, et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab. 2003;88:4413-7.
20. Freda P, Chung W, Matsuoka N, et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary. 2007;10:275-82.
21. Nault JC, Fabre M, Couchy G, et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol. 2012;56:184-91.
22. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-74.
23. Yamada M, Sekine S, Ogawa R, et al. Frequent activating GNAS mutations in villous adenoma of the colorectum. J Pathol. 2012;228:113-8.
24. Freda PU, Chung WK, Matsuoka N, et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary. 2007;10:275-82.
25. Nishihara E, Amino N, Maekawa K, et al. Prevalence of TSH receptor and Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan. Endocr J. 2009;56:791-8.
26. Tominaga E, Tsuda H, Arao T, et al. Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2010;118:160-6.